Gilead

Biogen Idec, Adimab expand collaboration

Friday, July 26, 2013 03:05 PM

Adimab, a provider of an integrated antibody discovery and optimization platform, has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. 

More... »

eFFECTOR Therapeutics raises $45M in series A financing

Wednesday, May 22, 2013 11:32 AM

eFFECTOR Therapeutics, a newly established biopharmaceutical company, has completed a $45 million Series A financing. eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer. 

More... »

Chimerix appoints Michael Rogers as chief development officer

Monday, March 18, 2013 09:40 AM

Chimerix, a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed Michael D. Rogers, Ph.D., as chief development officer.

More... »

Gilead Sciences acquires YM BioSciences

Wednesday, February 6, 2013 11:12 AM

The Supreme Court of Nova Scotia has issued a final order approving the previously announced plan involving YM BioSciences, Gilead Sciences and Nova Scotia Limited, a wholly-owned subsidiary of Gilead. Nova Scotia Limited will acquire all of the issued and outstanding common shares of YM BioSciences for cash consideration of $2.95 per common share.

More... »

Gilead touts positive results in two phase III studies of sofosbuvir for Hep C

Monday, February 4, 2013 02:14 PM

Gilead Sciences, a biopharmaceutical company based in Foster City, Calif., released top line results from two phase III studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

More... »

Gilead initiates phase III program for tenofovir alafenamide for HIV

Friday, January 25, 2013 11:30 AM

Gilead Sciences, a biopharmaceutical company based in Foster City, Calif., has initiated the first of two phase III clinical trials (Study 104) evaluating a single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults.

More... »

MacroGenics, Gilead Sciences to develop four DART products

Monday, January 7, 2013 01:47 PM

MacroGenics, a privately held biotechnology company that develops next generation antibody therapeutics, has entered into a license agreement with Gilead Sciences, a biopharmaceutical company focused on unmet medical needs, for the development and commercialization of Dual-Affinity Re-Targeting (DART) products directed at up to four undisclosed targets.

More... »

Gilead Sciences to acquire YM Biosciences

Wednesday, December 12, 2012 11:17 AM

Gilead Sciences, a biopharmaceutical company based in Foster City, Calif., has signed a definitive agreement to acquire YM BioSciences, a drug development company based in Canada, for $2.95 per share in cash. 

More... »

Chimerix appoints Michelle Berrey as CMO

Monday, November 19, 2012 10:45 AM

Chimerix, a Durham, N.C.-based biotechnology company developing orally-available antiviral therapeutics, has appointed Michelle Berrey, MD, MPH, as chief medical officer.

More... »

Gilead to build new R&D facility

Wednesday, November 14, 2012 11:13 AM

Gilead Alberta ULC, a wholly-owned subsidiary of biopharmaceutical company Gilead Sciences, has entered an agreement with Eco Industrial Business Park to purchase and develop 10 acres of land at 1250 Hayter Road, in North East Edmonton, Canada. The transaction is anticipated to close in January 2013.

More... »